Bellerophon Therapeutics — Corporate Update (March 2020)
16 slides from Bellerophon Therapeutics's corporate update, Mar 31, 2020
Slide 1: Bellerophon Therapeutics COVID-19 Overview
Bellerophon Therapeutics COVID-19 Overview I March 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi
Slide 3: Bellerophon Therapeutics (BLPH) Company Profile
Bellerophon Therapeutics (BLPH) Company Profile • Focused on developing inhaled nitric oxide (iNO) based therapies for outpatient management of chronic Clinical-Stage cardiopulmonary diseases and COVID-19 Biotherapeutics • Portable, lightweight delivery system (INOpulse®) allows for chronic home use
Slide 4: Investment Highlights
Investment Highlights Established iNO Therapeutic Benefit ✓ Approved for acute treatment of persistent pulmonary hypertension in neonates ✓ Positive results from multiple Phase 2 studies support INOpulse MoA and benefit Advanced Clinical Stage Product INOpulse technology focused on several large unm
Slide 5: Highly Experienced Leadership Team
Highly Experienced Leadership Team Jonathan Peacock 10 years experience as CFO at Amgen and Novartis Chairman Pharma Fabian Tenenbaum 15 years of executive-level experience in finance, BD Chief Executive Officer and operations Hunter Gillies, M.D. 20 years experience in clinical research specializin
Slide 6: INOpulse Delivery System Overview
INOpulse Delivery System Overview Portable Delivery System Allows Chronic iNO Therapy Antifungal Immuno-modulator Antiviral Vasodilator Antibacterial Wound Healing Promotor Nitric Oxide Novel drug-device combination therapy with multiple mechanisms of action Well established vasodilator approved for
Slide 7: INOpulse Delivery System: Lightweight, Portable and User Friendly
INOpulse Delivery System Lightweight, Portable and User Friendly Cannula Drug & Battery Key & Connector Power Indicators Alarm Swing engagement with drug 01 cartridge Intuitive and simple user 02 interface Oxygen Sources Tri-lumen cannula allows direct 03 connection with oxygen Lightweight portable
Slide 8: Pulsatile Inhaled Nitric Oxide: Potential Treatment Option for COVID-19
Pulsatile Inhaled Nitric Oxide: Potential Treatment Option for COVID-19 • FDA granted emergency expanded access for pulsatile inhaled nitric oxide for treating Coronavirus (COVID- 19); first patient has initiated treatment - Also known as compassionate use, administered on a per-patient basis, at ti
Slide 9: COVID-19 Treatment Paradigm
COVID-19 Treatment Paradigm Inhaled Nitric Oxide: Potential Therapy for Stage II Patients Stage I Stage II Stage III (Early infection) (Pulmonary Phase) (Hyperinflammation Phase) IIA IIB Viral response phase Host inflammatory response phase Severity of illness Severity Time Course Mild constitutiona
Slide 10: Nitric Oxide Plays a Key Role in Suppressing Viral Replication
Nitric Oxide Plays a Key Role in Suppressing Viral Replication Naturally produced immune response to invading pathogens Endogenous NO production is upregulated by macrophages as a defense mechanism against pathogen infections Virus replication has been shown to correlate with NO production with inhi
Slide 11: In Vitro Testing Verifies Antiviral Effect of NO on SARS Coronavirus
In Vitro Testing Verifies Antiviral Effect of NO on SARS Coronavirus SNAP (NO donor) reduces viral load and inhibits viral replication of SARS-CoV SNAP (NO donor) reduces viral load after 24 hours SNAP (NO donor) stops RNA production Cells infected with SARS CoV and treated with different Cells infe
Slide 12: NO Improves Survival of SARS Infected Cells
NO Improves Survival of SARS Infected Cells SNAP (NO donor) concentration over 250µM improves cellular survival Increased survival rate of SARS infected cells by the treatment Percent protection achieved in SARS-CoV infected cells. of SNAP. Optical density (492nm) was measured to determine Bars indi
Slide 13: Inhaled NO Provides Benefit in Patients Infected with SARS-CoV
Inhaled NO Provides Benefit in Patients Infected with SARS-CoV iNO improves arterial oxygenation and reduces pneumonia infiltrates in SARS patients Patients demonstrated improved arterial oxygenation Progression of pneumonia (May 29-June 2); Effect of iNO therapy and reduced need for ventilation sup
Slide 14: Inhaled NO Provides Benefit in Patients Infected with SARS-CoV
Inhaled NO Provides Benefit in Patients Infected with SARS-CoV iNO reduces need for mechanical ventilation post-treatment and improves chest x-ray Need For Ventilatory Support Post- Chest X-Ray Treatment 90% 70% 80% 60% 70% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% iNO Control Improved No Ch
Slide 15: Next Steps in COVID-19
Next Steps in COVID-19 FDA has granted emergency expanded access to allow pulsatile inhaled nitric oxide to be used as supportive treatment for COVID-19 Access allows treatment under the care and supervision of a physician on a named patient basis, with first patient dosed in March 2020 Bellerophon
Slide 16: Investor Contacts
Investor Contacts Fabian Tenenbaum Chief Executive Officer BTInvestorRelations@bellerophon.com Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com 212-915-2578
Bellerophon Therapeutics — Corporate Update (March 2020) on 6ix